Journal
← Tickers

LLY

LLY — Ruslan Averin's Analysis · 2 entries

  1. Eli Lilly Q3 2026 Earnings Preview: $22.6B Consensus, Mounjaro and Zepbound, Foundayo's First Full Quarter, Guidance
    ·7 min read

    Eli Lilly Q3 2026 Earnings Preview: $22.6B Consensus, Mounjaro and Zepbound, Foundayo's First Full Quarter, Guidance

    Eli Lilly Q3 2026 earnings: revenue $24.4B vs $22.6B LSEG, EPS $7.48, Mounjaro $10.7B, Foundayo $184M, 2026 guide raised to $91–92B; stock +6.6%.

  2. The Obesity Pill Is Approved — Eli Lilly Reports Tomorrow With Everything to Prove
    ·6 min read

    The Obesity Pill Is Approved — Eli Lilly Reports Tomorrow With Everything to Prove

    Ruslan Averin on August 4: Lilly reports August 5 with the Street at $20.26B and $6.71. The FDA has approved its oral GLP-1 — now the launch has to show up.